Analysis and opinion on monthly deal activity, along with the trend for thelast six months for merger and acquisition (M&A), private equity, privateplacement, IPO, and secondary offering deals.

India has emerged as a strong base for clinical trials in recent times. Due to the multitude of benefits it offers, the country is fast growing as a centre for conducting clinical trials for many international companies.

The Actavis Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Otsuka Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The report explores the best methods of exploiting legislation to maximise revenue generation and protecting the considerable investments associated with innovations.

The Shire Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

A global analytical guide and comparative analysis of international destinations, with location attractiveness index

The Merger and Acquisition Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the merger and acquisition (M&A) agreements entered into by the worlds leading biopharma companies

The Roche Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Wyeth Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Counterfeit medicines are a global problem costing patient’s their health and the pharmaceutical industry and governmental organizations millions of dollars per year. Although there is no one preventative strategy, there are several measures that

The Gilead Sciences Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Merck & Co Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Baxter Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Ratiopharm Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Due to the unique nature of the pharmaceutical industry there are a number of challenges to be overcome in the installation of CRM solutions.

The Clinical Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access tthe clinical stage partnering agreements entered intby the worlds leading biopharma companies.

The Co-promotion and Co-marketing Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies

The Teva Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Allergan Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Pharmaceutical competitive intelligence (CI) helps drive decision-making processes across an organization. As a forward-thinking, proactive support function, CI influences business development and brand management, among other areas.

Analysis and opinion on monthly deal activity, along with the trend for the last six months for merger and acquisition (M&A), private equity, private placement, IPO, and secondary offering deals.

The Mitsubishi Tanabe Pharmaceuticals Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

As market pressures demand increased innovation and shorter time-to-market product lifecycles, pharmaceutical companies are evaluating alternative business models, focusing on technologies such as business intelligence (BI) tools -for translational me

The Genentech Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Daiichi Sankyo Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

This brief offers an analysis of the technology components that will enable translational research in the pharmaceutical industry.

The Solvay Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Distribution Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.